LCN2 and acute kidney injury: NGAL is the most widely studied biomarker of AKI which is upregulated and released into circulation in response to renal tubular injury, and is commonly used in the clinical setting as an early biomarker of subclinical AKI to determine prognosis [52,53,54,55] and AKI severity [56,57,58].